# EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

> **NCT06715449** · PHASE2,PHASE3 · RECRUITING · sponsor: **University of East Anglia** · enrollment: 100 (estimated)

## Conditions studied

- Embolic Stroke of Undetermined Source
- Atrial Fibrillation New Onset

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT06715449
- **Lead sponsor:** University of East Anglia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2026-07
- **Final completion:** 2029-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715449, "EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06715449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*